Search results for "DEGRADATION"

showing 10 items of 1208 documents

Prolidase deficiency in two dermatological patients in western Sicily

2020

Prolidase deficiency is a rare disorder inherited through an autosomal recessive gene. The hallmark of the disorder are iminodipeptiduria, chronic skin ulcers, recurring infections, mental retardation and characteristic facial appearance, although prolidase deficiency can occur with no clinical manifestation. The primary biological function of the enzyme involves the metabolism of collagen degradation products and the recycling of proline for collagen resynthesis. We describe two patients with prolidase deficiency and review the different clinical manifestations suggesting the pathogenetic mechanism through few hypotheses.

Adult030203 arthritis & rheumatologyProlidase deficiencyCollagen degradationbusiness.industryDermatologyClinical manifestationmedicine.disease030207 dermatology & venereal diseases03 medical and health sciencesFacial appearanceChronic skin ulcers0302 clinical medicineImmunologymedicineHumansFemaleProlidase deficiency ulcersProlidase DeficiencyIminodipeptiduriabusinessSicilyGiornale Italiano di Dermatologia e Venereologia
researchProduct

The role of body muscle mass as an indicator of activity in inflammatory bowel disease patients

2020

Malnutrition is an objective disease activity parameter for patients with inflammatory bowel disease (IBD), particularly Crohn's Disease (CD), and is an indicator of lesion expansion or inflammatory activity. Active disease is correlated with the systemic response of the body's immune system, activating a hypermetabolic state and protein degradation (Argiles JM, 2015). These conditions lead to malnutrition, which significantly increases the risk of impaired clinical outcomes, such as delayed recovery or increased mortality (Landi F, 2019). Our aim was to identify malnutrition parameters associated with more pronounced metabolic status changes in IBD patients (i.e., classified as by low and …

AdultMale0301 basic medicinemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismPilot Projects030209 endocrinology & metabolismProtein degradationInflammatory bowel diseaseEnteral administration03 medical and health sciences0302 clinical medicineWeight lossInternal medicinemedicineHumansMedical historyProspective StudiesNot evaluated030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryMusclesInflammatory Bowel Diseasesmedicine.diseaseMalnutritionParenteral nutritionColitis UlcerativeFemalemedicine.symptombusinessClinical Nutrition ESPEN
researchProduct

Age Differences in Face Processing: The Role of Perceptual Degradation and Holistic Processing

2017

Abstract Objectives We simultaneously investigated the role of three hypotheses regarding age-related differences in face processing: perceptual degradation, impaired holistic processing, and an interaction between the two. Methods Young adults (YA) aged 20–33-year olds, middle-age adults (MA) aged 50–64-year olds, and older adults (OA) aged 65–82-year olds were tested on the context congruency paradigm, which allows measurement of face-specific holistic processing across the life span (Meinhardt-Injac, Persike & Meinhardt, 2014. Acta Psychologica, 151, 155–163). Perceptual degradation was examined by measuring performance with faces that were not filtered (FSF), with faces filtered to …

AdultMaleAgingSocial Psychologymedia_common.quotation_subjectContext (language use)050105 experimental psychologyYoung Adult03 medical and health sciences0302 clinical medicineSignal strengthAge groupsFace perceptionPerceptionHumans0501 psychology and cognitive sciencesAgedmedia_commonAged 80 and overAge differences05 social sciencesMiddle AgedClinical PsychologyFace (geometry)FemaleGeriatrics and GerontologyPsychologyFacial RecognitionGerontology030217 neurology & neurosurgeryCognitive psychologyDegradation (telecommunications)The Journals of Gerontology: Series B
researchProduct

Deferral of assessment of pulmonary embolism

2007

We evaluated a simplified algorithm for safely postponing diagnostic imaging for pulmonary embolism (PE). At the index visit, patients were identified as being at high or low risk of PE; the former received full dosage low molecular weight heparin while the latter were left untreated until performance of diagnostic imaging (max 72 hours). During this period, no thromboembolic events occurred in low-risk patients (0/211, 0.% [upper 95% CI 0.9%]); only one event occurred in those at high-risk (1/125, 0.8% [upper 95% CI, 1.2]). Our study demonstrates that diagnostic imaging for PE can be safely deferred for up to 3 days.

AdultMaleRiskmedicine.medical_specialtyTime Factorsmedicine.drug_classLow molecular weight heparinThrombophiliaVentilation/perfusion ratioFibrin Fibrinogen Degradation ProductsPredictive Value of TestsThromboembolismD-dimerPrevalenceVentilation-Perfusion RatiomedicineHumansThrombophiliaAgedAged 80 and overVenous Thrombosisbusiness.industryRespiratory diseaseAnticoagulantsHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryHospitalizationVenous thrombosisEarly DiagnosisTreatment OutcomePredictive value of testsFemalePulmonary EmbolismbusinessTomography Spiral ComputedAlgorithmsHaematologica
researchProduct

Significance of hyperlactatemia in acute hypnotic drug poisoning

1981

Lactate concentration, fibrinogen and fibrin(ogen) -- degradation-products in central venous blood were analysed in 35 unconscious patient with acute hypnotic drug poisoning (HDP) and compared with the results in 13 healthy control persons undergoing the same degree of forced diuresis via central venous catheters. Blood samples were taken on admission and at 12 h intervals up to 36 h after admission. Patients with HDP were attributed to the categories of moderate intoxications (n = 17) and severe intoxications (n = 18) according to their clinical condition. On admission, blood lactate was significantly higher in severe intoxication (3.90 +/- 2.94 mmol/l) as compared to the control group (1.…

AdultMaleUnconsciousnessFibrinogenFibrinFibrin Fibrinogen Degradation ProductsDrug DiscoverymedicineBlood lactateHumansHypnotics and SedativesIn patientGenetics (clinical)biologybusiness.industryUnconsciousnessHemodynamicsFibrinogenGeneral MedicineVenous bloodHypnotic drugAnesthesiaLactatesbiology.proteinMolecular MedicineFemaleHyperlactatemiamedicine.symptombusinessmedicine.drugKlinische Wochenschrift
researchProduct

Should we look for silent pulmonary embolism in patients with deep venous thrombosis?

2014

Background Asymptomatic or silent pulmonary embolism (S-PE) in patients with deep vein thrombosis has been the focus of numerous publications with the objective of determining the incidence of S-PE and assessing whether its existence has any clinical or therapeutic consequences that outweigh the risks associated with the diagnostic tests performed and the increased healthcare costs. The objectives were to assess the incidence of S-PE using computed tomography angiogram (CTA), to understand the epidemiological factors that might trigger embolism, and to assess whether D-dimer (DD) predicts the existence of S-PE’s. Methods A prospective and consecutive assessment of 103 hospitalized patients …

AdultMalemedicine.medical_specialtyAdolescentDeep veinAsymptomaticFibrin Fibrinogen Degradation ProductsYoung AdultDeep vein thrombosisHumansMedicineProspective StudiesProspective cohort studyAgedAngiologyAged 80 and overVenous Thrombosisbusiness.industryIncidencePulmonary embolismMiddle Agedmedicine.diseaseThrombosisPulmonary embolismRadiographyVenous thrombosismedicine.anatomical_structureEmbolismD-dimerAsymptomatic DiseasesFemaleRadiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesResearch ArticleBMC Cardiovascular Disorders
researchProduct

Deferment of Objective Assessment of Deep Vein Thrombosis and Pulmonary Embolism Without Increased Risk of Thrombosis

2004

Background: Treatment of patients with suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) is problematic if diagnostic imaging is not immediately available. Pretest clinical probability (PCP) and D-dimer assessment can be used to identify patients for whom empirical protective anticoagulation is indicated. To evaluate whether PCP and D-dimer assessment, together with the use of low-molecular-weight heparins (LMWHs), allow objective appraisal of DVT and PE to be deferred for up to 72 hours, patients with suspected DVT and PE were prospectively examined. Methods: Patients identified with a high PCP or a moderate PCP with positive D-dimer test results received a protective full-do…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classDeep veinLow molecular weight heparinFibrin Fibrinogen Degradation ProductsD-dimerInternal MedicinemedicineHumansRisk factoranticoagulationAgedAged 80 and overVenous ThrombosisPatientVascular diseasebusiness.industrylow molecular weight heparinAnticoagulantdeep vein thrombosisuspected PEHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureD dimerFemalePulmonary EmbolismbusinessAlgorithmsFollow-Up StudiesArchives of Internal Medicine
researchProduct

Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina

1991

PAI-1 antigen, tPA antigen and thrombin - antithrombin III complexes (TAT) levels were measured in 10 males with stable angina and type-II diabetes mellitus and in 16 males with stable angina without diabetes or other risk factors (hyperfibrinogenaemia, hyperlipidaemia, diabetes, hypertension, smoking and obesity) known to increase PAI levels. Ten healthy men of equivalent age served as controls. Because only diabetics with coronary artery disease (CAD) showed a decreased fibrinolytic capacity, a second study was performed on the 16 non-diabetic CAD patients to determine whether submaximal workload induces significant changes of tPA and PAI levels. TAT levels were increased in CAD, and sign…

AdultMalemedicine.medical_specialtyAntithrombin IIICoronary DiseaseStable anginaAngina PectorisFibrin Fibrinogen Degradation ProductsCoronary artery diseaseThrombinAntigenDiabetes mellitusInternal medicinemedicineHumanscardiovascular diseasesAgedbusiness.industryFibrinolysisPlasminogen activator inhibitor antigenAntithrombinFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseObesityPlasminogen InactivatorsEndocrinologyDiabetes Mellitus Type 2Tissue Plasminogen ActivatorExercise TestbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism

2019

Renal impairment, a source of chronic hypercoagulability[1][1] and inflammation,[2][2] is known to reduce the specificity of the D-dimer test in the diagnosis of venous thromboembolism (VTE).[3][3] This leads to many false positives in such patients and consequently to additional costs, as well as

AdultMalemedicine.medical_specialtyComputed Tomography AngiographyRenal functionSensitivity and SpecificityFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineText miningInternal medicineD-dimermedicineFalse positive paradoxHumansFalse Positive ReactionsProspective StudiesRenal InsufficiencyProspective cohort studyOnline Only ArticlesComputed tomography angiographyAgedProbabilityVenous Thrombosismedicine.diagnostic_testbusiness.industryHematologyVenous ThromboembolismMiddle AgedCardiologyFemalebusinessPulmonary EmbolismVenous thromboembolismAlgorithms030215 immunologyGlomerular Filtration RateHaematologica-the Hematology Journal
researchProduct

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Inst…

2018

: Recommended strategy for venous thromboembolism (VTE) diagnosis includes the use of sensitive D-dimer (DDi) assays along with pretest probability (PTP) assessment. The Clinical and Laboratory Standards Institute (CLSI) recently issued a guideline (US FDA endorsed) on DDi in VTE exclusion. Such guideline specifies the ideal D-dimer assay characteristics and target population. Demonstrate STA-LiatestD-Di performance combined with a PTP score for proximal deep vein thrombosis (pDVT) exclusion in a CLSI compliant study. International, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard-of-care setting. DDi was measured in DVT-sus…

AdultMalemedicine.medical_specialtyDeep veinShort Communications030204 cardiovascular system & hematologySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsSTA-Liatest DDi03 medical and health sciences0302 clinical medicineInternal medicineOutpatientsD-dimermedicineHumansProspective StudiesProspective cohort studyexclusiondeep venous thrombosisAgedVenous ThrombosisUnited States Food and Drug Administrationbusiness.industryImmunoturbidimetryHematologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseThrombosisUnited StatesPulmonary embolismClinical trialPre- and post-test probabilitymedicine.anatomical_structureD-dimerFemalebusiness030215 immunologyBlood Coagulation & Fibrinolysis
researchProduct